BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19904804)

  • 1. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.
    Lee DH; Kim SW; Suh C; Lee JS; Ahn JS; Ahn MJ; Park K; Na II; Lee JC; Ryoo BY; Yang SH
    Cancer; 2010 Jan; 116(1):132-6. PubMed ID: 19904804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.
    Hong J; Jung M; Kim YJ; Sym SJ; Kyung SY; Park J; Lee SP; Park JW; Cho EK; Jeong SH; Shin DB; Lee JH
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):215-20. PubMed ID: 21691745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
    Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS
    Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer.
    Lim S; Cho BC; Jung JY; Kim GM; Kim SH; Kim HR; Kim HS; Lim SM; Park JS; Lee JH; Kim D; Kim EY; Park MS; Kim YS; Kim SK; Chang J; Kim JH
    Lung Cancer; 2013 Jun; 80(3):313-8. PubMed ID: 23510628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
    Kim SJ; Kim JS; Kim SC; Kim YK; Kim YK; Kang JY; Yoon HK; Song JS; Lee SH; Moon HS; Kim JW; Kim KH; Kim CH; Shim BY; Kim HK
    Lung Cancer; 2010 Jun; 68(3):446-9. PubMed ID: 19683359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
    Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer.
    Chen YM; Perng RP; Yang KY; Wu HW; Lin WC; Liu JM; Tsai CM; Whang-Peng J
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Aug; 63(8):605-11. PubMed ID: 10969446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
    Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
    Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
    Rhee CK; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim CH; Shim BY; Kim HK; Sun DS; Kim KH
    Lung Cancer; 2011 Apr; 72(1):64-7. PubMed ID: 20832894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
    Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
    J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
    Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
    Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
    Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
    Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
    Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
    Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer.
    Yeo CD; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim KH; Shim BY; Kim CH
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):809-14. PubMed ID: 23918044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
    Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.